Loading...
Intra-articular Syringe Condrotide Polynucleotides 2% 2 Ml Mastelli
5% off
€57,23
€60,00
Unit price
/
Unavailable
Tax included, shipping and discounts calculated at checkout.
Mastelli | SKU:
939969073
Intra-articular Syringe Condrotide Polynucleotides 2% 2 Ml Mastelli is backordered and will ship as soon as it is back in stock.
Shipping Costs and Times
Shipping Costs and Times
- Order fulfilled in 24h
- Italy, including islands, Free from €49.90
- Orders under €49.90: €4.99
- Europe starting from €11
Payments
Payments
Payment information is processed securely. We do not store credit card information or have access to your credit card information.
Returns and Refunds
Returns and Refunds
You can return and receive a refund for the item within 30 days. See full policy here.
Intra-articular Syringe Condrotide Polynucleotides 2% 2 Ml Mastelli
€57,23
€60,00
Unit price
/
Unavailable
Do you need help?
Our customer service is here to help you!
- Contact us by phone, email or WhatsApp, from Monday to Friday, from 9:00 to 20:00 .
- For common questions, such as tracking your order or checking its fulfillment status, you can count on our artificial intelligence , available 24/7 .
We are always at your side to offer you fast and effective support!
Description
Description
INTRA-ARTICULAR SYRINGE CONDROTIDE POLYNUCLEOTIDES 2% 2 ML MASTELLI
Condrotide 2 ml
Description
Medical device.
Gel for intra-articular infiltrations with polynucleotides.
Viscoelastic, transparent, colorless solution: it comes in the form of a pre-filled, sterile, pyrogen-free, single-use glass syringe, containing 2 ml of solution. Polynucleotides are highly purified, of fish origin, and have a concentration of 20 mg/ml.
It is characterized by its viscoelasticity and a high capacity to bind numerous water molecules, therefore allowing it to lubricate and promote the normalization of synovial fluid viscosity.
Thanks to its viscoelastic and lubricating properties, Condrotide promotes the restoration of the rheological and physiological conditions of the joints. By improving the characteristics of the synovial fluid, it exerts a protective action on the joints and promotes the physiological repair mechanisms at the level of the articular cartilage. These properties contribute to both the improvement of joint function and the reduction of painful symptoms.
Instructions for use
Inject into the joint cavity, using a sterile needle with a diameter between 18 G and 22 G, generally 20 G. As a guideline, unless otherwise advised by a doctor, infiltrate 2 ml of product (40 mg of polynucleotides) intra-articularly once a week for 3-6 weeks.
Intra-articular infiltration must be performed by medical personnel, observing the technical and aseptic standards prescribed for these administration methods. Given the viscosity of the solution, to ensure a watertight seal and prevent product leakage between the needle and syringe during administration, firmly screw the needle onto the Luer-type closing collar of the syringe.
Components
Each pre-filled syringe contains: polynucleotides 20 mg/ml, water for injections, sodium chloride, monobasic sodium phosphate dihydrate, dibasic sodium phosphate dodecahydrate.
Warnings
Condrotide is designed for single use.
It should be used with particular caution in the presence of lymphatic or venous stasis in the leg to be treated.
In the presence of joint effusion, aspiration is recommended before injecting the product.
It is advisable to recommend to the patient, after intra-articular injection, to avoid strenuous physical activities for the joint and to resume normal activities after a couple of days.
Do not inject intravascularly, outside the joint cavity, into the synovial tissue or into the joint capsule.
Do not inject if impurities are noticed in the syringe.
The use of Condrotide is contraindicated in subjects with hypersensitivity to the components of the product or with a positive history of allergy to products of fish origin.
Condrotide must not be injected in the presence of an infected or severely inflamed joint or if the patient has an infection near the infiltration site, to avoid the possibility of bacterial arthritis.
The efficacy and safety of Condrotide have not been established in patients with autoimmune diseases, in pregnant or breastfeeding women, and in children. Treatment in these cases is not recommended.
Adverse events associated with the practice of intra-articular injections are possible, such as: pain, feeling of warmth, redness, or swelling. These secondary manifestations can be contained by resting the joint and applying ice locally. Normally, they disappear after a short time. If symptoms persist, consult a doctor.
The doctor must ensure that patients inform them of any undesirable effects that have occurred after treatment.
Keep out of reach of children.
Intra-articular injection can only be performed by medical personnel.
Check the integrity of the syringe packaging before use: do not use CONDROTIDE if the packaging is already open or damaged.
Once opened, Condrotide must be used immediately and disposed of after use.
Do not disperse into the environment after use.
Condrotide must only be administered by authorized personnel in accordance with local legislation.
Storage
Store the container tightly closed, below 25 °C, away from light and heat. Do not freeze.
Shelf life unopened: 36 months.
Format
2 ml syringe
Code. MD033VEU
Medical device.
Gel for intra-articular infiltrations with polynucleotides.
Viscoelastic, transparent, colorless solution: it comes in the form of a pre-filled, sterile, pyrogen-free, single-use glass syringe, containing 2 ml of solution. Polynucleotides are highly purified, of fish origin, and have a concentration of 20 mg/ml.
It is characterized by its viscoelasticity and a high capacity to bind numerous water molecules, therefore allowing it to lubricate and promote the normalization of synovial fluid viscosity.
Thanks to its viscoelastic and lubricating properties, Condrotide promotes the restoration of the rheological and physiological conditions of the joints. By improving the characteristics of the synovial fluid, it exerts a protective action on the joints and promotes the physiological repair mechanisms at the level of the articular cartilage. These properties contribute to both the improvement of joint function and the reduction of painful symptoms.
Instructions for use
Inject into the joint cavity, using a sterile needle with a diameter between 18 G and 22 G, generally 20 G. As a guideline, unless otherwise advised by a doctor, infiltrate 2 ml of product (40 mg of polynucleotides) intra-articularly once a week for 3-6 weeks.
Intra-articular infiltration must be performed by medical personnel, observing the technical and aseptic standards prescribed for these administration methods. Given the viscosity of the solution, to ensure a watertight seal and prevent product leakage between the needle and syringe during administration, firmly screw the needle onto the Luer-type closing collar of the syringe.
Components
Each pre-filled syringe contains: polynucleotides 20 mg/ml, water for injections, sodium chloride, monobasic sodium phosphate dihydrate, dibasic sodium phosphate dodecahydrate.
Warnings
Condrotide is designed for single use.
It should be used with particular caution in the presence of lymphatic or venous stasis in the leg to be treated.
In the presence of joint effusion, aspiration is recommended before injecting the product.
It is advisable to recommend to the patient, after intra-articular injection, to avoid strenuous physical activities for the joint and to resume normal activities after a couple of days.
Do not inject intravascularly, outside the joint cavity, into the synovial tissue or into the joint capsule.
Do not inject if impurities are noticed in the syringe.
The use of Condrotide is contraindicated in subjects with hypersensitivity to the components of the product or with a positive history of allergy to products of fish origin.
Condrotide must not be injected in the presence of an infected or severely inflamed joint or if the patient has an infection near the infiltration site, to avoid the possibility of bacterial arthritis.
The efficacy and safety of Condrotide have not been established in patients with autoimmune diseases, in pregnant or breastfeeding women, and in children. Treatment in these cases is not recommended.
Adverse events associated with the practice of intra-articular injections are possible, such as: pain, feeling of warmth, redness, or swelling. These secondary manifestations can be contained by resting the joint and applying ice locally. Normally, they disappear after a short time. If symptoms persist, consult a doctor.
The doctor must ensure that patients inform them of any undesirable effects that have occurred after treatment.
Keep out of reach of children.
Intra-articular injection can only be performed by medical personnel.
Check the integrity of the syringe packaging before use: do not use CONDROTIDE if the packaging is already open or damaged.
Once opened, Condrotide must be used immediately and disposed of after use.
Do not disperse into the environment after use.
Condrotide must only be administered by authorized personnel in accordance with local legislation.
Storage
Store the container tightly closed, below 25 °C, away from light and heat. Do not freeze.
Shelf life unopened: 36 months.
Format
2 ml syringe
Code. MD033VEU
Product Details
Product Details
-
Legislative class
-
Deductible Product